Gå direkt till huvudinnehållet

Adhd hos barn och unga

Senast reviderad:
Sakkunnig:
Definition:
Tillstånd präglat av varaktiga störningar i koncentrations-/uppmärksamhetsförmågan och/eller motorisk hyperaktivitet och impulsivitet. Symtomen ska ha noterats före tolv års ålder och ha en direkt negativ inverkan på sociala aktiviteter och aktiviteter inom studier/arbete.
Förekomst:
Prevalensen för adhd bland barn uppskattas till 3–7 %.
Symtom:
Huvudsymtom är störningar i koncentration och uppmärksamhet, motorisk hyperaktivitet och ökad impulsivitet.
Kliniska fynd:
Symtomen leder ofta till beteendestörningar och dålig funktion socialt och i skolan.
Diagnostik:
Diagnos ställs inom den barnpsykiatriska vården efter en grundlig utredning.
Behandling:
Multimodal behandling med pedagogiska, psykologiska/psykiatriska, medicinska och psykosociala åtgärder.
  1. Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet. 2016. pmid:26386541 PubMed  
  2. Riktlinje adhd. Svenska föreningen för barn- och ungdomspsykiatri (SFBUP) 2016. Hämtad 2022-11-03 slf.se  
  3. Polanczyk GV, Salum GA, Sugaya LS, Caye A, Rohde LA. Annual research review: A meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. J Child Psychol Psychiatry. 2015 Mar;56(3):345-65. doi: 10.1111/jcpp.12381. Epub 2015 Feb 3. PMID: 25649325 PubMed  
  4. Nationella riktlinjer för vård och stöd vid adhd och autism Prioriteringsstöd till beslutsfattare och chefer 2022. Socialstyrelsen. Hämtad 2022-11-03. www.socialstyrelsen.se  
  5. Kooij JJS, Bijlenga D, Salerno L et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. Eur Psychiatry. 2019 Feb;56:14-34. doi: 10.1016/j.eurpsy.2018.11.001. Epub 2018 Nov 16. PMID: 30453134 PubMed  
  6. Statistikdatabas för läkemedel. Socialstyrelsen. Adhd-läkemedel (hämtad 2022-11-08) sdb.socialstyrelsen.se  
  7. BUSA Behandlingsuppföljning av säkerställd ADHD. Årsrapport 2019. registercentrum.blob.core.windows.net  
  8. Faraone SV, Larsson H. Genetics of attention deficit hyperactivity disorder. Mol Psychiatry. 2019 Apr;24(4):562-575. doi: 10.1038/s41380-018-0070-0. Epub 2018 Jun 11. PMID: 29892054 PubMed  
  9. Sprich S, Biederman J, Crawford MH, Mundy E and Faraone SV. Adoptive and biological families of children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2000; 39: 1432-7. PubMed  
  10. Carlsson T, Molander F, Taylor MJ, Jonsson U, Bölte S. Early environmental risk factors for neurodevelopmental disorders - a systematic review of twin and sibling studies published online ahead of print, 2020 Jul 24. Dev Psychopathol. 2020;1-48. PMID: 32703331 PubMed  
  11. Faraone SV, Asherson P, Banaschewski T et al. Attention-deficit/hyperactivity disorder. Nat Rev Dis Primers 2015; Aug 6;1: 15020. pmid:2718926512. Arnsten AF, Rubia K. Neurobiological Circuits Regulating Attention, Cognitive Control, Motivation, J Am Acad Child Adolesc Psychiatry. 2012;51(4):356-67. PMID: 22449642. 13. Volkow ND, Swanson JM. Clinical practice: Adult attention deficit-hyperactivity disorder. N Engl J Med. 2013 Nov 14;369(20):1935-44. 29. Hoogman M, Bralten J, Hibar DP et al. Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults: a cross-sectional mega-analysis. The Lancet Psychiatry , 2017 [url]http://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(17)30049-4/fulltext[/url] PMID: 27189265 PubMed  
  12. Arnsten AF, Rubia K. Neurobiological Circuits Regulating Attention, Cognitive Control, Motivation, J Am Acad Child Adolesc Psychiatry. 2012;51(4):356-67. PMID: 22449642.
  13. Hoogman M, Bralten J, Hibar DP et al. Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults: a cross-sectional mega-analysis. The Lancet Psychiatry, Feb 2017. PMID: 28219628 PubMed  
  14. Volkow ND, Swanson JM. Clinical practice: Adult attention deficit-hyperactivity disorder. N Engl J Med. 2013 Nov 14;369(20):1935-44. PubMed  
  15. Stöd till barn, ungdomar och vuxna med adhd – ett kunskapsstöd. Socialstyrelsen (2014). www.socialstyrelsen.se  
  16. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005; 366: 237-48. PubMed  
  17. Southammakosane C, Schmitz K, et al. Pediatric Psychopharmacology for Treatment of ADHD, Depression, and Anxiety. Pediatrics. 2015 Aug;136(2):351-9. PubMed  
  18. Läkemedel vid adhd - behandlingsrekommendation. Läkemedelsverket 2016. Uppdaterad 2020. Hämtad 2022-11-09. www.lakemedelsverket.se  
  19. Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018 Sep;5(9):727-738. doi: 10.1016/S2215-0366(18)30269-4. Epub 2018 Aug 7. PMID: 30097390 PubMed  
  20. The MTA Cooperative Group. National Institute of Mental Health Multimodal treatment study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 2004; 113: 762-9. PMID: 15060225. PubMed  
  21. The MTA Cooperative Group. National Institute of Mental Health Multimodal treatment study of ADHD follow-up: 24 month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics 2004; 113: 754-61. PMID: 15060224. PubMed  
  22. Matthijssen AM, Dietrich A, Bierens M et al. Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study. Am J Psychiatry 2019. pmid:31109200 PubMed  
  23. Sömnstörningar hos barn – kunskapsdokument. Läkemedelsverket (2015). www.lakemedelsverket.se  
  24. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006; 354: 1445-8. PubMed  
  25. Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 2011; 365: e-pub. PMID: 22043968. PubMed  
  26. Stuhec M, Munda B, Svab V, et al. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion. J Affect Disord. 2015 Jun 1;178:149-59. PubMed  
  27. Punja S, Shamseer L, Hartling L et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev 2016; Feb 4;2: CD009996. pmid:26844979. PubMed  
  28. Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs 2009;11(3):203-26. PubMed  
  29. Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry. 2014 Feb;53(2):174-87. doi: 10.1016/j.jaac.2013.11.005. Epub 2013 Nov 26. PMID: 24472252 PubMed  
  30. Kratochvil CJ, Heiligenstein JH, Dittmann R et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002; 41: 776-84. PubMed  
  31. Starr LH, Kemner JE, Ciccone PE et al. Comparison of treatment outcomes in children with ADHD: a discussion on the Formal Observation of Concerta® versus Strattera® (FOCUS) study. J Nat Med Ass 2004; 96: 876. PubMed  
  32. Spencer TJ, Newcorn JH, Kratochvil CJ, Ruff D, Michelson D, Biederman J. Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder. Pediatrics 2005; 116: e74-e80. PMID: 15995021. PubMed  
  33. Wilens TE, Robertson B, Sikirica V, Harper L, Young JL, Bloomfield R, Lyne A, Rynkowski G, Cutler AJ. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. 2015 Nov;54(11):916-25.e2. doi: 10.1016/j.jaac.2015.08.016. Epub 2015 Sep 15. PMID: 26506582 PubMed  
  34. Sallee FR, McGough J, Wigal T, Donahue J, Lyne A, Biederman J; SPD503 STUDY GROUP. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009 Feb;48(2):155-65. doi: 10.1097/CHI.0b013e318191769e. PMID: 19106767 PubMed  
  35. Cortese S, Ferrin M, Brandeis D, et al. Cognitive training for attention-deficit/hyperactivity disorder: meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials. J Am Acad Child Adolesc Psychiatry. 2015 Mar;54(3):164-74. Epub 2014 Dec 29.pmid: 25721181. PubMed  
  36. Lopez PL, Torrente FM, Ciapponi A, Lischinsky AG, Cetkovich-Bakmas M, Rojas JI, Romano M, Manes FF. Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2018 Mar 23;3(3):CD010840. doi: 10.1002/14651858.CD010840.pub2. PMID: 29566425 PubMed  
  37. Edbom T, Lichtenstein P, Granlund M og Larsson JO. Long-term relationship between symptoms of Attention Deficit Hyperactivity Disorder and self-esteem in a prospective longitudinal study of twins. Acta Pædiatrica 2006; 95: 650-7. PubMed  
  38. Klein RG, Mannuzza S, Olazagasti MA, Roizen E, Hutchison JA, Lashua EC, Castellanos FX. Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. Arch Gen Psychiatry. 2012 Dec;69(12):1295-303. doi: 10.1001/archgenpsychiatry.2012.271. PMID: 23070149 PubMed  
  39. Dalsgaard S, Østergaard SD, Leckman JF, Mortensen PB, Pedersen MG. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet. 2015 May 30;385(9983):2190-6. doi: 10.1016/S0140-6736(14)61684-6. Epub 2015 Feb 26. PMID: 25726514 PubMed  
  40. Hegvik TA, Instanes JT, Haavik J, Klungsøyr K, Engeland A. Associations between attention-deficit/hyperactivity disorder and autoimmune diseases are modified by sex: a population-based cross-sectional study. Eur Child Adolesc Psychiatry. 2018 May;27(5):663-675. doi: 10.1007/s00787-017-1056-1. Epub 2017 Oct 5. Erratum in: Eur Child Adolesc Psychiatry. 2017 Dec 1;: PMID: 28983730 PubMed  
  41. Cortese S, Moreira-Maia CR, St Fleur D, Morcillo-Peñalver C, Rohde LA, Faraone SV. Association Between ADHD and Obesity: A Systematic Review and Meta-Analysis. Am J Psychiatry. 2016 Jan;173(1):34-43. doi: 10.1176/appi.ajp.2015.15020266. Epub 2015 Aug 28. PMID: 26315982 PubMed  
  42. Instanes JT, Klungsøyr K, Halmøy A, Fasmer OB, Haavik J. Adult ADHD and Comorbid Somatic Disease: A Systematic Literature Review. J Atten Disord. 2018 Feb;22(3):203-228. doi: 10.1177/1087054716669589. Epub 2016 Sep 1. PMID: 27664125 PubMed  
  43. Posner J, Polanczyk GV, Sonuga-Barke E. Attention-deficit hyperactivity disorder. Lancet. 2020 Feb 8;395(10222):450-462. doi: 10.1016/S0140-6736(19)33004-1. Epub 2020 Jan 23. PMID: 31982036 PubMed  
  44. Sonuga-Barke EJ. Casual models of Attention-deficit/hyperactivity disorder: from common simple deficits to multiple developmental pathways. Biol Psychiatry 2005; 57: 1231-8. PubMed  
  45. Cheon KA, Ryu YH, Kim YK, Namkoong K, Kim CH and Lee JD. Dopamine transporter density in the basal ganglia assessed with 123IIPT SPET in children with attention deficit hyperactivity disorder. Eur J Nucl Med Mol Imag 2003; 30: 306-11. PubMed  
  • Kerstin Malmberg, med dr och överläkare, Bup Stockholm sektion Västra
  • Anna Nager, docent och specialist i allmänmedicin, Karolinska institutet